Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Multimin North America is a U.S.-based animal health company focused on injectable trace mineral supplementation for cattle. Its lead and apparently primary commercial product is MULTIMIN 90, an FDA-approved prescription animal drug that provides zinc, copper, manganese, and selenium by subcutaneous injection. The product is marketed for beef and dairy cattle as a strategic supplement to support mineral status during key production and stress periods. The company operates in veterinary pharmaceuticals and animal nutrition rather than human biopharma, with commercial activity centered in the United States and broader international brand presence through the Multimin franchise. Public materials also indicate a relationship with Axiota Animal Health, whose site now hosts current MULTIMIN product information and the April 2024 FDA approval announcement.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Multimin North America.